Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Inchcape Q1 revenues fall 5pc

(Sharecast News) - Automotive distributor Inchcape said on Thursday that revenues had fallen amid what it called an "uncertain market environment" during Q1. Inchcape said group revenues were down 5% at £2.1bn, with new vehicle sales slipping 3% and underlying total insurable value falling 4%. Group organic revenue was 5% lower and reported revenues dropped 8%.

The FTSE 250-listed group said it had seen a continued improvement in performance in the Americas, with further growth throughout Q1, while it had experienced continuing headwinds in several key markets in the Asia-Pacific region and lower revenues in Europe & Africa, driven by order bank unwind.

Chief executive Duncan Tait said: "We achieved further operational and strategic progress during the first quarter, evidenced by market share gains in key markets and several contract wins, and the progression of our £250.0m share buyback programme. As the leading global automotive distributor, Inchcape remains well-positioned to support our key stakeholders in navigating the current market uncertainty, as our experienced leadership team has done during challenging market environments in previous years."

Tait also noted that demand was not currently being impacted by the "dynamic and complex tariff situation", although he does expect to see potential impacts on supply from Inchcape's OEMs, as well as from the "competitive environment and market demand".

As of 0925 BST, Inchcape shares were down 6.72% at 645.50p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.